The effect of prostaglandins on ox pituitary content of adenosine 3':5'-cyclic monophosphate and the release of growth hormone.
1. An assay, based on competition between adenosine 3':5'-cyclic monophosphate (cyclic AMP) and cyclic [(3)H]AMP for binding to a rabbit skeletal muscle protein, has been used to measure tissue contents of cyclic AMP. The assay has a sensitivity of 0.05pmol of cyclic AMP. Cyclic GMP and cyclic CMP have 0.5%, and cyclic IMP 6.5%, of the ability of cyclic AMP to displace cyclic [(3)H]AMP from binding protein; AMP, ADP and ATP have no effect. 2. By using this method, the cyclic AMP content of ox pituitary slices exposed to prostaglandin was determined; release of growth hormone was measured by radioimmunoassay. 3. Release of growth hormone was increased by 45min incubation in 1mum-prostaglandin E(2) in the absence of theophylline, or in 10nm-prostaglandin E(2), 0.1mum-prostaglandin A(1) or 1mum-prostaglandin B(1) in the presence of 0.5mm-theophylline. 4. Pituitary cyclic AMP content was increased by 10min incubation in 1mum-prostaglandin E(2) in the absence of theophylline, or in 0.1mum-prostaglandin E(2) in the presence of 0.5mm-theophylline. 5. The maximum increase in cyclic AMP content was observed 10min, and significant changes in growth hormone release 30min, after introduction of prostaglandin E(2). 6. The increase in pituitary cyclic AMP content, but not in the rate of release of growth hormone, was observed in the absence of external Ca(2+). 7. The stimulation of release of growth hormone by prostaglandin was decreased by preincubation of tissue for 2h in colchicine (100mum) or cytochalasin B (10mug/ml). 8. These results support the suggestion that increased release of growth hormone after treatment with prostaglandin is the result of increased tissue cyclic AMP content, and possibly involves a microfilamentous or microtubular protein.
D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002417:Cattle; D003078:Colchicine / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism; D003597:Cytosine Nucleotides / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism*; D066298:In Vitro Techniques; D007292:Inosine Nucleotides / Q000378:metabolism; D008870:Microtubules / Q000378:metabolism; D010472:Perchlorates / Q000494:pharmacology; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism*; D011453:Prostaglandins / Q000494:pharmacology*; D011485:Protein Binding; D011506:Proteins / Q000378:metabolism; D011863:Radioimmunoassay; D013806:Theophylline / Q000494:pharmacology; D013997:Time Factors; D014238:Trichloroacetic Acid / Q000494:pharmacology; D014316:Tritium
D003597:Cytosine Nucleotides; D007292:Inosine Nucleotides; D010472:Perchlorates; D011453:Prostaglandins; D011506:Proteins; D014316:Tritium; D014238:Trichloroacetic Acid; D013006:Growth Hormone; D013806:Theophylline; D000242:Cyclic AMP; D006152:Cyclic GMP; D003078:Colchicine; D002118:Calcium